Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Camphikefish on Jan 28, 2024 3:19pm

2 things

To me, a guy trying to simply use common sense, it comes down to two things in my mind:

1. A potential unvillingmess to move outside the shift towards vaccines and gene therapy to embrace a complete paradigm shift in treatment modalities

and/or

2. A low apetite for super high efficacy rates with less frequent treatments thus hindering stable cash flow reimbursements already in play with the other treatment algorithms. 


It's what they know and what they're comfortable with. I work with orthopedic surgeons and they adopt change at a snails pace and do not like to be first timer pioneer types. Cancer treatment might just be the same type animal. 

Also, is someone lobbying to hold us back? I do not know just throwing it out there. The manipulation from a trading standpoint seems obvious however, this is a different aspect of the overall scenario. Occam's Razor in play here perhaps? Or maybe it's just something as simple as was posted the other day. The stock and technology simply need to be derisked further. Given the need for viable treatment options and patents coming due, it sure seems if we are on the radar, some entity would have to make a play this year if BTD is granted. I hope and pray for no rs split whatsoever. Not sure I could deal with it very well.

Finally, Matthew Perraton is as kind and generous as one could ask for. Why does it seem to me, with all due respect, he seems a bit out of his league as it pertains to dealing with the likes of Merck & JNJ. So I wish him the absolute best and will always be thankful for his kindness. I just did not get any warm and fuzzies about our prospects for financing in the near term. Then again, he can not say much, and then there's my subjective nature which could skew the reality of what all is truly in play here. I concede that. Just want some hope, traction, and movement since bladder brain and lung are all huge targets for most every major player out there. We have potentially somewhat derisked, viable options teed up and just need money to push forward. Still grasping for Hope out here and staying put. Please pardon the rambling. Let's go Libiati, throw us a bone with some meat on it please!

Comment by enriquesuave on Jan 28, 2024 5:12pm
Big Pharma will be able to charge the same amount with Ruvidar with way less treatments and with way lower cost of drug production.  3 treatments for $300k or 25 for $300 K makes Ruvidar way more profitable and a major time saver to treat more cases  IMO   
Comment by enriquesuave on Jan 28, 2024 5:17pm
Urologists should like it even more as well.  They can treat 7-9 patients vs 1 patient in the same amount of op time .  Definitely good for Big Pharmaceutical, Urologists and patients who will need less treatments.  
Comment by Camphikefish on Jan 28, 2024 5:27pm
Thank you Enrique. I agree. Seems like the people who make acquisitions and partnering deals do not see it yet. My question is why. 
Comment by patience69 on Jan 28, 2024 6:12pm
Camp & Enrique. I could not agree with you guys more. Why is Merck for one doing trials with everybody to try to extend the patent life of keytruda & we just sit there out of cash? Obviously they have a ton to lose. Is it because we are a drug & a device? Is it because they dont perceive us as a threat? What the heck are they waiting for???
Comment by 99942Apophis on Jan 29, 2024 11:08am
patience69, your post raises the possibility that Merck is aware of Theralase and could be (1) trying to find a way to top TLT  CR percentages (2) in negotiations with TLT for partnership (3) buyout 
Comment by Alamir1111 on Jan 29, 2024 11:15am
https://www.cnbc.com/amp/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html
Comment by thadeush on Jan 29, 2024 12:43pm
I'd be very surprised if Merck or any big drug company was NOT aware of TLT. That doesn't necessarily make TLT unique - I'm sure every drug/process that makes it to Phase 2 must be watched very carefully by big pharma for potential acquisition. The average investor may not be aware of Theralase, but there's probably a whole department evaluating promising new companies to see who ...more  
Comment by Longholder99 on Jan 28, 2024 6:17pm
I don't think anything big will happen on the JV front  untiil BTD which is what TLT is working on now.  New unapproved tech needs BTD as a derisking factor before a big company is going to pile in.  I suspect the shorting is hedge fund driven and simple profiteering on an easy target.  BTD within a few months I hope. Followed by institutional investment that if there is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250